Skip to main content

Advertisement

SpringerLink
Log in

Prevalence of Autoimmune Liver Disease Related Autoantibodies in Chinese Patients with Primary Biliary Cirrhosis

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

The prevalence of autoimmune liver disease (AiLD)-related autoantibodies has not been defined in Chinese patients with primary biliary cirrhosis (PBC) and therefore needs to be characterized.

Aims

The purpose of this study was to explore the prevalence of AiLD-related autoantibodies in Chinese patients with PBC.

Methods

Indirect immunofluorescence was used to detect anti-mitochondrial antibodies (AMA) in the sera from 198 PBC, 44 autoimmune hepatitis (AIH) and 41 non-autoimmune liver disease controls (LDC). ELISA assays were used to test the presence of anti-M2, anti-gp210, anti-sp100, anti-SLA, anti-LC1 and anti-LKM-1 antibodies.

Results

AMA was present in 92.4, 15.9 and 7.3%, respectively, of patients with PBC, AIH and LDC. Anti-M2 was present in 87.4% of the PBC patients, but only in 4.5 and 4.9%, respectively, of AIH and LDC patients. Anti-gp210 and anti-sp100 were detected in 34.3 and 25.8% of PBC, 6.8 and 15.9% of AIH and in 4.9 and 17.1% of LDC patients. Anti-LC1, anti-SLA and anti-LKM-1 were, respectively, present in 1.5, 0.0 and 0.5% of PBC, and 9.1, 11.4 and 2.3% of AIH, and none of LDC. PBC patients that were AMA-positive presented with higher IgM levels but lower CRP levels than negative ones. ALT, TBIL, DBIL, GGT, ALP, and AST were detected at higher levels and ALB at lower levels in PBC positive for anti-gp210 (P < 0.05).

Conclusions

The prevalence of AiLD-related autoantibodies we provided might help define PBC in China. Anti-sp100 is not a better prognostic marker for Chinese PBC patients compared to anti-gp210. The identification of effective diagnostic biomarkers for AMA-negative PBC patients is still needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005;353:1261–1273.

    Article  PubMed  CAS  Google Scholar 

  2. Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology. 2002;123:1044–1051.

    Article  PubMed  Google Scholar 

  3. Kim WR, Lindor KD, Locke GR 3rd, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology. 2000;119:1631–1636.

    Article  PubMed  CAS  Google Scholar 

  4. Selmi C, Invernizzi P, Zuin M, Podda M, Gershwin ME. Genetics and geoepidemiology of primary biliary cirrhosis: following the footprints to disease etiology. Semin Liver Dis. 2005;25:265–280.

    Article  PubMed  Google Scholar 

  5. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology. 2000;31:1005–1013.

    Article  PubMed  CAS  Google Scholar 

  6. He XS, Ansari AA, Ridgway WM, Coppel RL, Gershwin ME. New insights to the immunopathology and autoimmune responses in primary biliary cirrhosis. Cell Immunol. 2006;239:1–13.

    Article  PubMed  CAS  Google Scholar 

  7. Kita H. Autoreactive CD8-specific T-cell response in primary biliary cirrhosis. Hepatol Res. 2007;37:S402–S405.

    Article  PubMed  CAS  Google Scholar 

  8. Hu CJ, Zhang FC, Li YZ, Zhang X. Primary biliary cirrhosis: what do autoantibodies tell us? World J Gastroenterol. 2010;16:3616–3629.

    Article  PubMed  CAS  Google Scholar 

  9. Miyakawa H, Kawashima Y, Kitazawa E, et al. Low frequency of anti-SLA/LP autoantibody in Japanese adult patients with autoimmune liver diseases: analysis with recombinant antigen assay. J Autoimmun. 2003;21:77–82.

    Article  PubMed  CAS  Google Scholar 

  10. Vitozzi S, Djilali-Saiah I, Lapierre P, Alvarez F. Anti-soluble liver antigen/liver-pancreas (SLA/LP) antibodies in pediatric patients with autoimmune hepatitis. Autoimmunity. 2002;35:485–492.

    Article  PubMed  CAS  Google Scholar 

  11. Wong GL, Hui AY, Wong VW, Chan FK, Sung JJ, Chan HL. A retrospective study on clinical features and prognostic factors of biopsy-proven primary biliary cirrhosis in Chinese patients. Am J Gastroenterol. 2005;100:2205–2211.

    Article  PubMed  Google Scholar 

  12. Liu H, Liu Y, Wang L, et al. Prevalence of primary biliary cirrhosis in adults referring hospital for annual health check-up in Southern China. BMC Gastroenterol. 2010;10:100.

    Article  PubMed  Google Scholar 

  13. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938.

    Article  PubMed  CAS  Google Scholar 

  14. Berg PA, Klein R, Lindenborn-Fotinos J, Klöppel W. ATPase-associated antigen (M2): marker antigen for serological diagnosis of primary biliary cirrhosis. Lancet. 1982;2:1423–1426.

    Article  PubMed  CAS  Google Scholar 

  15. Invernizzi P, Crosignani A, Battezzati PM, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology. 1997;25:1090–1095.

    Article  PubMed  CAS  Google Scholar 

  16. Muratori P, Muratori L, Gershwin ME, et al. ‘True’ antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? Clin Exp Immunol. 2004;135:154–158.

    Article  PubMed  CAS  Google Scholar 

  17. Liu B, Shi XH, Zhang FC, Zhang W, Gao LX. Antimitochondrial antibody-negative primary biliary cirrhosis: a subset of primary biliary cirrhosis. Liver Int. 2008;28:233–239.

    Article  PubMed  Google Scholar 

  18. Sakauchi F, Mori M, Zeniya M, Toda G. Antimitochondrial antibody negative primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid. J Epidemiol. 2006;16:30–34.

    Article  PubMed  Google Scholar 

  19. Milkiewicz P, Buwaneswaran H, Coltescu C, Shums Z, Norman GL, Heathcote EJ. Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease. Clin Gastroenterol Hepatol. 2009;7:1355–1360.

    Article  PubMed  Google Scholar 

  20. Nezu S, Tanaka A, Yasui H, et al. Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis. J Gastroenterol Hepatol. 2006;21:1448–1454.

    PubMed  CAS  Google Scholar 

  21. Montano-Loza AJ, Carpenter HA, Czaja AJ. Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis. J Clin Gastroenterol. 2008;42:1047–1053.

    Article  PubMed  Google Scholar 

  22. Nakamura M, Kondo H, Mori T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology. 2007;45:118–127.

    Article  PubMed  CAS  Google Scholar 

  23. Bogdanos DP, Liaskos C, Pares A, et al. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology. 2007;45:1583.

    Article  PubMed  Google Scholar 

  24. Muratori P, Muratori L, Ferrari R, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol. 2003;98:431–437.

    Article  PubMed  Google Scholar 

  25. Itoh S, Ichida T, Yoshida T, et al. Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol. 1998;13:257–265.

    Article  PubMed  CAS  Google Scholar 

  26. Züchner D, Sternsdorf T, Szostecki C, Heathcote EJ, Cauch-Dudek K, Will H. Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology. 1997;26:1123–1130.

    PubMed  Google Scholar 

  27. Miyachi K, Hankins RW, Matsushima H, et al. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. J Autoimmun. 2003;20:247–254.

    Article  PubMed  CAS  Google Scholar 

  28. Liu HY, Deng AM, Zhou Y, Yao DK, Xu DX, Zhong RQ. Analysis of HLA alleles polymorphism in Chinese patients with primary biliary cirrhosis. Hepatobiliary Pancreat Dis Int. 2006;5:129–132.

    PubMed  CAS  Google Scholar 

  29. Invernizzi P, Battezzati PM, Crosignani A, et al. Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. J Hepatol. 2003;38:401–406.

    Article  PubMed  CAS  Google Scholar 

  30. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology. 2002;35:658–664.

    Article  PubMed  CAS  Google Scholar 

  31. Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut. 2002;51:259–264.

    Article  PubMed  CAS  Google Scholar 

  32. Vitozzi S, Lapierre P, Djilali-Saiah I, Alvarez F. Autoantibody detection in type 2 autoimmune hepatitis using a chimera recombinant protein. J Immunol Methods. 2002;262:103–110.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Supported by the National Natural Science Foundation of China (Nos. 81072486, 30872331), and the Youth Foundation of Beijing Union Medical College Hospital (No. I10143).

Conflict of interest

We declare that we have no conflict of interest to disclose.

Author information

Authors and Affiliations

  1. Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, No.41 Da Mu Cang, Western District, Beijing, 100032, People’s Republic of China

    Chaojun Hu, Chuiwen Deng, Wen Zhang, Shulan Zhang, Xi Li, Ping Li, Fengchun Zhang & Yongzhe Li

  2. Beijing Institute of Genomics, Chinese Academy of Sciences, B-6 Airport Industrial Zone, Beijing, 101318, People’s Republic of China

    Guang Song

Authors
  1. Chaojun Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chuiwen Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guang Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shulan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xi Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ping Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fengchun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yongzhe Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Fengchun Zhang or Yongzhe Li.

Additional information

Chaojun Hu, Chuiwen Deng, and Guang Song equally contributed to this work and should be considered as the first authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hu, C., Deng, C., Song, G. et al. Prevalence of Autoimmune Liver Disease Related Autoantibodies in Chinese Patients with Primary Biliary Cirrhosis. Dig Dis Sci 56, 3357–3363 (2011). https://doi.org/10.1007/s10620-011-1756-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-011-1756-1

Keywords

Search

Navigation